AbbVie’s new drug application for Rinvoq (upadacitinib) received FDA approval on Aug. 16.
- 15mg, oral tablet extended release
- Indicated for treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate
©2019 Bloomberg L.P. All rights reserved. Used with permission
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.